within Pharmacolibrary.Drugs.ATC.A;

model A10BB05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 1.8333333333333333e-05,
    adminDuration  = 600,
    adminMass      = 250 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.009,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0005666666666666667,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A10BB05</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Tolazamide is a first-generation sulfonylurea oral hypoglycemic agent used for the management of type 2 diabetes mellitus. It stimulates pancreatic beta cells to release insulin. Tolazamide was widely used in the past but has largely been replaced by newer agents; however, it is still approved for clinical use in some regions.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are estimated for healthy adult subjects after single oral dosing, based on available secondary literature summaries and standard references.</p><h4>References</h4><ol><li><p>Harrower, AD (1996). Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency. <i>Clinical pharmacokinetics</i> 31(2) 111–119. DOI:<a href=\"https://doi.org/10.2165/00003088-199631020-00003\">10.2165/00003088-199631020-00003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8853933/\">https://pubmed.ncbi.nlm.nih.gov/8853933</a></p></li><li><p>Prendergast, BD (1984). Glyburide and glipizide, second-generation oral sulfonylurea hypoglycemic agents. <i>Clinical pharmacy</i> 3(5) 473–485. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/6435940/\">https://pubmed.ncbi.nlm.nih.gov/6435940</a></p></li><li><p>Gwilt, PR, et al., &amp; Tracewell, WG (1991). The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans. <i>Clinical pharmacokinetics</i> 20(6) 477–490. DOI:<a href=\"https://doi.org/10.2165/00003088-199120060-00004\">10.2165/00003088-199120060-00004</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2044331/\">https://pubmed.ncbi.nlm.nih.gov/2044331</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A10BB05;
